News Oragenics, Inc.

Equities

Delayed Nyse Other stock markets 20:08:45 30/04/2024 BST			5-day change	1st Jan Change
1.038 ^USD	+2.77%		-4.77%	-81.55%

04-12	North American Morning Briefing : Big Banks Kick -2-	DJ
03-29	Oragenics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards	04-19	BU
North American Morning Briefing : Big Banks Kick -2-	04-12	DJ
Oragenics, Inc. Files 10K and Provides Company Update	04-01	BU
Oragenics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-29	CI
Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion	03-18	BU
Oragenics Appoints James Kelly MD as Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion	03-18	CI
Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion	03-05	BU
Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion	03-05	CI
Oragenics Announces Closing of Public Offering	03-04	AQ
Oragenics Announces Closing of Public Offering	03-01	BU
Top Midday Decliners	02-28	MT
Oragenics Announces Pricing of Public Offering	02-28	BU
Oragenics Announces Proposed Public Offering	02-27	BU
Oragenics CEO Kimberly Murphy Steps Down, Board Chair to Serve as Interim Executive Chair	02-13	MT
Oragenics, Inc. Announces Leadership Transition	02-12	BU
Oragenics, Inc. Announces Leadership Transition	02-12	CI
Oragenics, Inc. Announces CEO Changes	02-12	CI
Oragenics, Inc. Announces Expiration of Its Investment Banking Engagement Agreement	02-07	BU
Oragenics, Inc. Preparing for Phase II Clinical Trials to Treat Concussion	02-05	BU
Oragenics, Inc. Prepares for Phase II Clinical Trials to Treat Concussion	02-05	CI

No results for this search